LeMaitre Vascular, Inc. - Common Stock (LMAT)
91.85
-8.06 (-8.07%)
Lemaitre Vascular is a medical device company focused on developing, manufacturing, and marketing innovative products for the treatment of vascular diseases
The company specializes in providing solutions for vascular surgeons, particularly in areas such as endovascular and open surgical procedures. Lemaitre Vascular offers a range of products, including synthetic grafts, stents, balloons, and devices used in the treatment of conditions such as peripheral artery disease and varicose veins. Through its commitment to research and development, the company aims to enhance patient outcomes and improve the effectiveness of vascular interventions.

Medical device company LeMaitre Vascular (NASDAQLMAT) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next quarter’s revenue guidance of $57.7 million underwhelmed, coming in 1.6% below analysts’ estimates. Its GAAP profit of $0.49 per share was in line with analysts’ consensus estimates.
Via StockStory · February 27, 2025

Medical device company LeMaitre Vascular (NASDAQLMAT)
will be announcing earnings results tomorrow after the bell. Here’s what to expect.
Via StockStory · February 26, 2025

Via Benzinga · December 17, 2024

On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72.
Via Investor's Business Daily · December 11, 2024

On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73.
Via Investor's Business Daily · December 3, 2024

Via Benzinga · November 1, 2024

ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth.
Via Investor's Business Daily · November 18, 2024

Via Benzinga · November 1, 2024

Via Benzinga · October 15, 2024

LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 1, 2024

On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77.
Via Investor's Business Daily · June 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSEGOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via Benzinga · February 27, 2024

Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71.
Via Investor's Business Daily · May 29, 2024

The “Sell in May and Go Away” adage is wrong for most investors.
Via Talk Markets · May 27, 2024

LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 2, 2024

On Tuesday, Inspire Medical Systems stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 78.
Via Investor's Business Daily · April 30, 2024

Via Benzinga · February 28, 2024

Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQLMAT) with an Outperform rating and a
Via Benzinga · September 6, 2023

Via Benzinga · September 6, 2023